Uptake of Orexigen's Contrave outpaces rivals

Orexigen Therapeutics Inc. (NASDAQ:OREX) said net U.S. sales of weight-loss drug Contrave naltrexone/ bupropion were $6.5 million in 4Q14,

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE